v3.25.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2025
Dec. 31, 2024
Current assets    
Cash and cash equivalents $ 3,881 $ 7,141
Research and development tax credit receivable 664 519
Prepaid expenses and other current assets 1,091 849
Total current assets 5,636 8,509
Property, plant and equipment, net 220 269
Right-of-use assets, net 54 120
Other assets, non-current   6
Total assets 5,910 8,904
Current liabilities    
Accounts payable and accrued expenses 1,439 1,791
Lease liabilities, current 24 47
Other current liabilities 639 450
Total current liabilities 2,102 2,288
Lease liabilities, non-current 21 25
Total liabilities 2,123 2,313
Commitments and contingencies (Note 7)
Stockholders' equity:    
Preferred stock, par value $0.0001 per share, 10,000,000 shares authorized, 856 shares issued and outstanding, at March 31, 2025 and December 31, 2024, respectively
Common stock, par value $0.0001 per share, 300,000,000 shares authorized, 3,620,217 and 3,590,217 shares issued and outstanding, at March 31, 2025 and December 31, 2024, respectively
Additional paid-in capital 122,651 122,316
Accumulated other comprehensive loss (2,110) (1,105)
Accumulated deficit (116,754) (114,620)
Total stockholders' equity 3,787 6,591
Total liabilities and stockholders' equity $ 5,910 $ 8,904

Source

HTML PDF
ZIP